- 期刊
- OpenAccess
Anti-IL-12/IL-23 Treatment for a Psoriatic Patient with Heart Failure
並列摘要
Introduction: Psoriasis is an inflammatory disorder characterized by a deregulation in the Thl/Th17/ Treg cells count and function. A plethora of new drugs called ＂biologicals＂ have been developed. Beside TNF-o blockers, new drugs interfering with the IL-23 axis have been introduced. Case Report: We present case of: a 59-year-old high-need psoriatic patient hospitalized for acute heart failure. Physicians decided to withdraw anti-TNF-o therapy because of NYHA class III and the need of cardlo-surgery, Surgery was delayed for his general conditions. The patient was referred to our department to establish a new therapy. A treatment wlth anti-IL-12/IL-23P40 was introduced. Ustekinumab was chosen for the high efficacy rates, the high safety profile and for the reported safety in NYHA class III/IV patients. The rapid general condition improvement enabled the patient to undergo surgery. Conclusion: Anti-TNF-u drugs are contraindicated in NYHA class III/IV patients. In those cases drugs interfering with different cytokine patterns could be of inte r est. Although anti-IL-12/IL-23P40 has been previously addressed as unsafe in NYHA class III/IV, the clinical practice suggests that this drug can be considered quite safe. Currently the role of antiIL-12/IL-23P40 on cardiovascular diseases is still an open question and deserves further investigations. Treatment with anti-IL-12/IL23P40 can be considered a good option in NYHA class III/IV patients and in high-need psoriasis patients.